Article citationsMore>>

Matoba, S., Tatsumi, T., Murohara, T., Imaizumi, T., Katsuda, Y., Ito, M., Saito, Y., Uemura, S., Suzuki, H., Fukumoto, S., Yamamoto, Y., Onodera, R., Teramukai, S., Fukushima, M., Matsubara H. and TACT Follow-up Study Investigators (2008) Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia, American Heart Journal, 156, 1010-1018. doi:10.1016/j.ahj.2008.06.025

has been cited by the following article:

• TITLE: Repeated application of autologous bone marrow-derived stem cell therapy in patients with severe Buerger’s disease

  AUTHORS: Zoltan Boda, K. Razso, M. Szarvas, Zs. Olah, P. Ilonczai, Z. Vereb, E. Rajnavolgyi

  KEYWORDS: Buerger’s disease, non healing ulcer, repeated bone marrow-derived stem cell therapy

  JOURNAL NAME: Stem Cell Discovery, Vol.1 No.1, March 4, 2011

  ABSTRACT: Stem cell therapy (SCT) is a promising and prospective approach in the treatment of patients with severe peripheral arterial disorders, primarily with Buerger’s disease. However, very little is known about the duration of the effect of SCT, and to our best knowledge no data are available on the efficacy and safety of repeated SCT in patients with Buerger’s disease. Here we report on two patients with severe Buerger’s disease, who received repeated autologous bone marrow-derived stem cell therapy. Our results show that a second SCT, applied to a previously treated leg 30 or 36 months after the first treatment was efficient in both cases. After twelve months, the clinical state of the repeatedly treated lower limb improved spectacularly and non-healing ulcers healed more rapidly than after the first SCT. No severe adverse events were detected. Thus repeated SCT offers a safe and efficient treatment option for relapsing patients at the advanced stage of Buerger’s disease.